Toll Free: 1-888-928-9744
Published: Dec, 2016 | Pages:
45 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2016, provides an overview of the Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline landscape. Vancomycin resistant staphylococcus infection is a condition caused by bacteria (germs). This infection occurs when bacteria, called Staphylococcus aureus or Staph, becomes resistant (not killed) to the antibiotic medicine vancomycin. Risk factors include taking strong antibiotics the wrong way may cause the bacteria to develop resistance to the antibiotics, weak immune system and staying in the hospital too long. Symptoms include fever, chills, cough, chest pain, trouble breathing, and a fast heartbeat. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Preclinical and Discovery stages are 2, 5 and 1 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 1 and 1 molecules, respectively.Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections. Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease). - The pipeline guide reviews pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 4 List of Figures 4 Introduction 5 Global Markets Direct Report Coverage 5 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections Overview 6 Therapeutics Development 7 Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Overview 7 Pipeline Products for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Comparative Analysis 8 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics under Development by Companies 9 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics under Investigation by Universities/Institutes 10 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline Products Glance 11 Clinical Stage Products 11 Early Stage Products 12 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Products under Development by Companies 13 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Products under Investigation by Universities/Institutes 14 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Companies Involved in Therapeutics Development 15 CrystalGenomics Inc 15 Debiopharm International SA 16 e-Therapeutics Plc 17 iNtRON Biotechnology Inc 18 Wockhardt Ltd 19 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Therapeutics Assessment 20 Assessment by Monotherapy Products 20 Assessment by Combination Products 21 Assessment by Target 22 Assessment by Mechanism of Action 24 Assessment by Route of Administration 26 Assessment by Molecule Type 28 Drug Profiles 30 (miconazole nitrate + nisin) - Drug Profile 30 Product Description 30 Mechanism Of Action 30 R&D Progress 30 CG-400549 - Drug Profile 31 Product Description 31 Mechanism Of Action 31 R&D Progress 31 Debio-1450 - Drug Profile 33 Product Description 33 Mechanism Of Action 33 R&D Progress 33 Epidermicin NI-01 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 SAL-200 - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 Small Molecule to Target Bacterial Cell Wall for MRSA and VRSA Infections - Drug Profile 37 Product Description 37 Mechanism Of Action 37 R&D Progress 37 Small Molecules to Activate Perforin-2 Synthesis for Bacterial Infections - Drug Profile 38 Product Description 38 Mechanism Of Action 38 R&D Progress 38 Small Molecules to Inhibit Oxacillinase for Gram-Positive Bacterial Infections - Drug Profile 39 Product Description 39 Mechanism Of Action 39 R&D Progress 39 SP-2078 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 WCK-4086 - Drug Profile 41 Product Description 41 Mechanism Of Action 41 R&D Progress 41 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects 42 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products 43 Appendix 44 Methodology 44 Coverage 44 Secondary Research 44 Primary Research 44 Expert Panel Validation 44 Contact Us 44 Disclaimer 4
List of Tables
Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections, H2 2016 7 Number of Products under Development for Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Comparative Analysis, H2 2016 8 Number of Products under Development by Companies, H2 2016 9 Number of Products under Investigation by Universities/Institutes, H2 2016 10 Comparative Analysis by Clinical Stage Development, H2 2016 11 Comparative Analysis by Early Stage Development, H2 2016 12 Products under Development by Companies, H2 2016 13 Products under Investigation by Universities/Institutes, H2 2016 14 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by CrystalGenomics Inc, H2 2016 15 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Debiopharm International SA, H2 2016 16 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by e-Therapeutics Plc, H2 2016 17 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by iNtRON Biotechnology Inc, H2 2016 18 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by Wockhardt Ltd, H2 2016 19 Assessment by Monotherapy Products, H2 2016 20 Assessment by Combination Products, H2 2016 21 Number of Products by Stage and Target, H2 2016 23 Number of Products by Stage and Mechanism of Action, H2 2016 25 Number of Products by Stage and Route of Administration, H2 2016 27 Number of Products by Stage and Molecule Type, H2 2016 29 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Dormant Projects, H2 2016 42 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Discontinued Products, H2 2016 43 Vancomycin-Resistant Staphylococcus aureus (VRSA) Infections - Pipeline by 21st Century Therapeutics Inc, H2 2016 45
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.